Friday, January 13, 2023 6:07:04 AM
As countries across the world have in recent months lifted all, or remaining pandemic-related restrictions and lockdowns, and as the COVID crisis looks to cool down, many health experts are not completely convinced that the pandemic has yet subsided.
At the start of July, the chief of the World Health Organization, Tedros Adhanom Ghebreyesus noted that a number of countries were still reporting a continuing rise in daily active cases, which in the long run can put severe pressure on public health systems and frontline workers.
While it's not yet clear when we will mark the end of the pandemic, Regencell Bioscience has made encouraging advances throughout the pandemic to establish new formulas and treatments for infectious diseases.
Separately, the company has been working on philanthropic projects that could help thousands of children who are in severe financial distress or have been impacted by COVID.
According to Yat-Gai, "In April, I started looking to provide grants and financial support to more than 10,000 children that have been financially impacted by COVID, and others affected with ADHD and ASD. Until now, I have managed to help over 150 children. This is a project I'm personally handling through the Regencell Foundation."
Investment in the future, whether through monetary means or philanthropic efforts, is slowly helping to reshape the human understanding of bioscience and biotechnology, and the impact it has to make a difference in the broader society it serves.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
Recent RGC News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 11:04:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/15/2023 11:09:52 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/27/2023 08:15:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM